Senti Biosciences (SNTI)
NASDAQ:SNTI
Want to see SNTI full AI Analyst Report?
SNTI Stock Chart & Stats
$1.10
-$0.36(-8.15%)
At close: 4:00 PM EST
$1.10
-$0.36(-8.15%)
Day’s Range― - ―
52-Week Range$0.77 - $3.40
Previous CloseN/A
Volume20.15K
Average Volume (3M)260.00K
Market Cap
$30.66M
Enterprise Value$35.22M
Total Cash (Recent Filing)$8.94M
Total Debt (Recent Filing)$19.14M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding31,144,754
10 Day Avg. Volume505,690
30 Day Avg. Volume260,000
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue926.96
Enterprise Value/Gross Profit-15.11
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$12.00Price Target Upside990.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$38.67K
Bulls Say, Bears Say
Bulls Say
Regulatory Clarity For SENTI-202Clear FDA feedback supporting a single-arm, multi-center pivotal path and RMAT/Orphan designations materially reduce regulatory uncertainty and can shorten timelines. This structural clarity improves the program's de-risking, partner interest, and potential for accelerated approval pathways over coming months.
Encouraging Early Clinical Efficacy SignalsDurable MRD-negative responses and a 50% composite CR rate in the Phase 1 cohort indicate meaningful biological activity for an off‑the‑shelf CAR‑NK approach. These reproducible efficacy signals plus incorporation into manufacturing reduce technical risk and support durable clinical differentiation and partnerability.
Structural Cost Reductions And Runway ActionsHalving lab/office footprint and renegotiating the master/sublease materially lowers fixed occupancy costs and operating burn. Combined with realized lease-related gain, this structural cost improvement extends runway and improves cash efficiency independent of short-term market moves.
Bears Say
Minimal Commercial RevenueThe company remains pre‑commercial with negligible product revenue and persistently large operating losses. That structural lack of recurring sales means long‑term viability depends on continual external financing or partnerships, raising execution risk if capital access tightens.
Fragile Balance Sheet And Asset ErosionSharp asset decline and a tiny equity base versus debt leave limited capital cushion to absorb trial delays or unexpected costs. High leverage and contracting assets increase the likelihood of dilutive financings or restrictive creditor protections, constraining strategic optionality over months.
Highly Onerous Convertible Financing TermsThe convertible note structure is secured, short‑maturity and carries punitive economics and full‑ratchet provisions. Structurally this raises dilution, creditor control and refinancing risk; if notes aren't converted it can force severe cash outflows or additional dilutive deals, impairing long‑term shareholder value.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences’s price range in the past 12 months?
Senti Biosciences lowest stock price was $0.77 and its highest was $3.40 in the past 12 months.
What is Senti Biosciences’s market cap?
Senti Biosciences’s market cap is $30.66M.
When is Senti Biosciences’s upcoming earnings report date?
Senti Biosciences’s upcoming earnings report date is Aug 18, 2026 which is in 66 days.
How were Senti Biosciences’s earnings last quarter?
Senti Biosciences released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.14.
Is Senti Biosciences overvalued?
According to Wall Street analysts Senti Biosciences’s price is currently Undervalued.
Does Senti Biosciences pay dividends?
Senti Biosciences does not currently pay dividends.
What is Senti Biosciences’s EPS estimate?
Senti Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences have?
Senti Biosciences has 31,144,754 shares outstanding.
What happened to Senti Biosciences’s price movement after its last earnings report?
Senti Biosciences reported an EPS of -$0.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.996%.
Which hedge fund is a major shareholder of Senti Biosciences?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senti Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (990.91% Upside)
$12.00 (990.91% Upside)
Hedge Fund Trend
Decreased
By 28.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-503.79%
Trailing 12-Months
Asset Growth
-53.80%
Trailing 12-Months
Company Description
Senti Biosciences
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
SNTI Stock 12 Month Forecast
Average Price Target
$12.00
▲(990.91% Upside)
Technical Analysis
Plus Therapeutics
―
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
―
Ownership Overview
2.63% Insiders
0.46% Mutual Funds
― Other Institutional Investors
95.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---